Gilead Sciences Q3 2026 Results: Net Income $2.43B, Down 20.4% YoY
Gilead Sciences reported total revenues of $8.3 billion for the third quarter of 2026, driven by $8.29 billion in product sales. Despite a profitable third quarter, the company recorded a net loss of $6.05 billion for the first nine months of 2026, primarily due to $11.3 billion in acquired in-process research and development expenses.
- Key figure
- Net income $2.43B · -20.4% YoY